SlideShare una empresa de Scribd logo
1 de 21
STANISLAV ALVARO CARDONA MEDICINE STUDENT INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   CDK1 INHIBITION SENSITISES AND TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   
FOLDING
FOLDING
The ovarian cancer is one of the most common in women. Some molecular particles are important to stop it. Inhibitors of the enzyme poly (ADP-ribose polymerase), or PARP, in a study to stop the development of some tumours
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     July 4th 2011
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     Ovarian cancer is a malignant tumor that arises in any part of the ovary due to mutation and cell proliferation influenced by genetic, environmental or hereditary factors.
Its prognosis is good, on the rare occasions when diagnosed early Ovarian cancer is the fifth most common cancer in women in the UK, all over the world, representing approximately 4% of all cancers diagnosed in women INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME    
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     There are several genes involved in the development of this pathology as BRCA1  BRCA2  RB1 NF1 FAT3 CSMD3 GABRA6 CDK12
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     This was determined by a genome study of women with ovarian cancer which showed mutations in the mRNA during protein synthesis
OBSERVATION I think that this is an important step in the science, because this would be the beginning of the treatment of many pathologies Understanding the genetic material allows find the answers for many medical riddles
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    July 4th 2011
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    Inhibitors of the enzyme poly (ADP-ribose) polymerase, or PARP, are among the most promising drugs currently in development as anti-tumour agents.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    BRCA1 "breast cancer 1"   is a tumor suppressor gene, which regulate the cell cycle and prevent uncontrolled proliferation.   CDK1 is a highly conserved protein that functions as a serine / threonine kinase, is encoded by the gene cdc2. Phosphorylation of these proteins control cell cycle progression
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    A combination of a PARP inhibitor with a Cdk1 inhibitor also showed reduced tumour growth and prolonged survival compared to treatment with one or no inhibitors in a mouse model of lung adenocarcinoma.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    Inhibition of Cdk1 is likely to sensitise tumours with wild type BRCA1 to PARP inhibition, and that a combination of inhibitors of these two enzymes may be a useful treatment for these tumours
OBSERVATION That experiments are fundamental to know how the human life is affected begging in the littlest process that define the whole life
MEDICAL UTILITY
MEDICAL UTILITY The study of the human genome could shed any information about each individual and that is where the solution begins each pathology to develop it.
MEDICAL UTILITY New experiments with enzymes have led to cures for various types of cancer, starting with the molecular basis of such tumors which involve cell division and proper transfer of genetic information. Molecular biology is the basis for understanding the processes that lead to cause such conditions, so find a solutions or improvements to the health of people
BIBLIOGRAPHY ,[object Object],[object Object],[object Object]
THANK YOU…

Más contenido relacionado

La actualidad más candente

Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
espontanea
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
European School of Oncology
 
SURE Conference Abstract
SURE Conference Abstract SURE Conference Abstract
SURE Conference Abstract
Eric Hillpot
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
MafeU
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
MafeU
 

La actualidad más candente (19)

Molecular Biology Seminary by Nicolas calle
Molecular Biology Seminary by Nicolas calleMolecular Biology Seminary by Nicolas calle
Molecular Biology Seminary by Nicolas calle
 
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Protocol for the Treatment Prostate Cancer - Dr Serge JurasunasProtocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
 
Seminario Biologia molecular pdf
Seminario Biologia molecular pdfSeminario Biologia molecular pdf
Seminario Biologia molecular pdf
 
Dna-Repair
Dna-RepairDna-Repair
Dna-Repair
 
Breast Cancer Facts, brought to you by Spencer Trask & Co.
Breast Cancer Facts, brought to you by Spencer Trask & Co.Breast Cancer Facts, brought to you by Spencer Trask & Co.
Breast Cancer Facts, brought to you by Spencer Trask & Co.
 
Role of tumour markers in clinical practice
Role of tumour markers in clinical practiceRole of tumour markers in clinical practice
Role of tumour markers in clinical practice
 
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
 
Alfred knudson and the two hit hypothesis
Alfred knudson and the two hit hypothesisAlfred knudson and the two hit hypothesis
Alfred knudson and the two hit hypothesis
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
 
Tumour Markers
Tumour Markers Tumour Markers
Tumour Markers
 
SURE Conference Abstract
SURE Conference Abstract SURE Conference Abstract
SURE Conference Abstract
 
tumor markers
tumor markerstumor markers
tumor markers
 
Tumour marker
Tumour markerTumour marker
Tumour marker
 
SERUM TUMOR MARKERS
SERUM TUMOR MARKERSSERUM TUMOR MARKERS
SERUM TUMOR MARKERS
 
Epithelial tumor markers
Epithelial tumor markersEpithelial tumor markers
Epithelial tumor markers
 
Prophylaxis and early diagnosis of breast cancer
Prophylaxis and early diagnosis of breast cancerProphylaxis and early diagnosis of breast cancer
Prophylaxis and early diagnosis of breast cancer
 
Papillary thyroid carcinoma
Papillary thyroid carcinomaPapillary thyroid carcinoma
Papillary thyroid carcinoma
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
 

Destacado

Ici 3 company profile
Ici 3 company profileIci 3 company profile
Ici 3 company profile
Kevin Lee
 
Virtual presentation assignment 1
Virtual presentation assignment 1Virtual presentation assignment 1
Virtual presentation assignment 1
Stalgis
 
Journal 4 to 5
Journal 4  to 5Journal 4  to 5
Journal 4 to 5
Kevin Lee
 
Journal 1 to 3
Journal 1 to 3Journal 1 to 3
Journal 1 to 3
Kevin Lee
 
ICI project 1
ICI project 1ICI project 1
ICI project 1
Kevin Lee
 
Arvoredeamigos
ArvoredeamigosArvoredeamigos
Arvoredeamigos
Claudia FN
 

Destacado (8)

Ici 3 company profile
Ici 3 company profileIci 3 company profile
Ici 3 company profile
 
Virtual presentation assignment 1
Virtual presentation assignment 1Virtual presentation assignment 1
Virtual presentation assignment 1
 
Journal 4 to 5
Journal 4  to 5Journal 4  to 5
Journal 4 to 5
 
Site report
Site reportSite report
Site report
 
Journal 1 to 3
Journal 1 to 3Journal 1 to 3
Journal 1 to 3
 
ICI project 1
ICI project 1ICI project 1
ICI project 1
 
Arvoredeamigos
ArvoredeamigosArvoredeamigos
Arvoredeamigos
 
Powerpoint
PowerpointPowerpoint
Powerpoint
 

Similar a Ovarian Cancer

Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre Arcaro
 
An introduction to cancer
An introduction to cancerAn introduction to cancer
An introduction to cancer
Salman Ul Islam
 
Personalized Medicine
Personalized MedicinePersonalized Medicine
Personalized Medicine
noelle cloven
 
Use of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancerUse of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancer
Isabelle Chiu
 

Similar a Ovarian Cancer (20)

Gene therapy
Gene therapyGene therapy
Gene therapy
 
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
 
Naturopathic Oncology Slideshare316
Naturopathic Oncology Slideshare316Naturopathic Oncology Slideshare316
Naturopathic Oncology Slideshare316
 
Russell
RussellRussell
Russell
 
Seminario biologia molecular
Seminario biologia molecular Seminario biologia molecular
Seminario biologia molecular
 
TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...
TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...
TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...
 
Anticancer
AnticancerAnticancer
Anticancer
 
An introduction to cancer
An introduction to cancerAn introduction to cancer
An introduction to cancer
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Personalized Medicine
Personalized MedicinePersonalized Medicine
Personalized Medicine
 
August 2018 Dil Se Dil Tak Newsletter (FOGSI)
August 2018   Dil Se Dil Tak Newsletter (FOGSI)August 2018   Dil Se Dil Tak Newsletter (FOGSI)
August 2018 Dil Se Dil Tak Newsletter (FOGSI)
 
ajit tumor marker.pptx
ajit tumor marker.pptxajit tumor marker.pptx
ajit tumor marker.pptx
 
CERVICAL CANCER
CERVICAL CANCERCERVICAL CANCER
CERVICAL CANCER
 
Tumour marker
Tumour marker Tumour marker
Tumour marker
 
How to Understand and Treat Cancer with Molecular Markers
How to Understand and Treat Cancer with Molecular MarkersHow to Understand and Treat Cancer with Molecular Markers
How to Understand and Treat Cancer with Molecular Markers
 
Advances in the management of breast cancer
Advances in the management of breast cancerAdvances in the management of breast cancer
Advances in the management of breast cancer
 
Cancer and tumor markers
Cancer and tumor markersCancer and tumor markers
Cancer and tumor markers
 
Use of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancerUse of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancer
 
Breast carcinoma overview and recent advances in management
Breast carcinoma overview and recent advances in managementBreast carcinoma overview and recent advances in management
Breast carcinoma overview and recent advances in management
 
Current pancreatic cancer research 10 May 16
Current pancreatic cancer research 10 May 16Current pancreatic cancer research 10 May 16
Current pancreatic cancer research 10 May 16
 

Último

Último (20)

IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and Planning
 
UiPath Test Automation using UiPath Test Suite series, part 1
UiPath Test Automation using UiPath Test Suite series, part 1UiPath Test Automation using UiPath Test Suite series, part 1
UiPath Test Automation using UiPath Test Suite series, part 1
 
THE BEST IPTV in GERMANY for 2024: IPTVreel
THE BEST IPTV in  GERMANY for 2024: IPTVreelTHE BEST IPTV in  GERMANY for 2024: IPTVreel
THE BEST IPTV in GERMANY for 2024: IPTVreel
 
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
Integrating Telephony Systems with Salesforce: Insights and Considerations, B...
Integrating Telephony Systems with Salesforce: Insights and Considerations, B...Integrating Telephony Systems with Salesforce: Insights and Considerations, B...
Integrating Telephony Systems with Salesforce: Insights and Considerations, B...
 
FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...
FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...
FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...
 
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptxWSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
 
Connecting the Dots in Product Design at KAYAK
Connecting the Dots in Product Design at KAYAKConnecting the Dots in Product Design at KAYAK
Connecting the Dots in Product Design at KAYAK
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
Strategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsStrategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering Teams
 
The UX of Automation by AJ King, Senior UX Researcher, Ocado
The UX of Automation by AJ King, Senior UX Researcher, OcadoThe UX of Automation by AJ King, Senior UX Researcher, Ocado
The UX of Automation by AJ King, Senior UX Researcher, Ocado
 
Buy Epson EcoTank L3210 Colour Printer Online.pdf
Buy Epson EcoTank L3210 Colour Printer Online.pdfBuy Epson EcoTank L3210 Colour Printer Online.pdf
Buy Epson EcoTank L3210 Colour Printer Online.pdf
 
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomSalesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
 
Buy Epson EcoTank L3210 Colour Printer Online.pptx
Buy Epson EcoTank L3210 Colour Printer Online.pptxBuy Epson EcoTank L3210 Colour Printer Online.pptx
Buy Epson EcoTank L3210 Colour Printer Online.pptx
 
ECS 2024 Teams Premium - Pretty Secure
ECS 2024   Teams Premium - Pretty SecureECS 2024   Teams Premium - Pretty Secure
ECS 2024 Teams Premium - Pretty Secure
 
Designing for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at ComcastDesigning for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at Comcast
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptxUnpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
 
AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101
 

Ovarian Cancer

  • 1. STANISLAV ALVARO CARDONA MEDICINE STUDENT INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME CDK1 INHIBITION SENSITISES AND TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION  
  • 4. The ovarian cancer is one of the most common in women. Some molecular particles are important to stop it. Inhibitors of the enzyme poly (ADP-ribose polymerase), or PARP, in a study to stop the development of some tumours
  • 5. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   July 4th 2011
  • 6. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   Ovarian cancer is a malignant tumor that arises in any part of the ovary due to mutation and cell proliferation influenced by genetic, environmental or hereditary factors.
  • 7. Its prognosis is good, on the rare occasions when diagnosed early Ovarian cancer is the fifth most common cancer in women in the UK, all over the world, representing approximately 4% of all cancers diagnosed in women INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME  
  • 8. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   There are several genes involved in the development of this pathology as BRCA1 BRCA2 RB1 NF1 FAT3 CSMD3 GABRA6 CDK12
  • 9. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   This was determined by a genome study of women with ovarian cancer which showed mutations in the mRNA during protein synthesis
  • 10. OBSERVATION I think that this is an important step in the science, because this would be the beginning of the treatment of many pathologies Understanding the genetic material allows find the answers for many medical riddles
  • 11. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   July 4th 2011
  • 12. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   Inhibitors of the enzyme poly (ADP-ribose) polymerase, or PARP, are among the most promising drugs currently in development as anti-tumour agents.
  • 13. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   BRCA1 "breast cancer 1" is a tumor suppressor gene, which regulate the cell cycle and prevent uncontrolled proliferation. CDK1 is a highly conserved protein that functions as a serine / threonine kinase, is encoded by the gene cdc2. Phosphorylation of these proteins control cell cycle progression
  • 14. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   A combination of a PARP inhibitor with a Cdk1 inhibitor also showed reduced tumour growth and prolonged survival compared to treatment with one or no inhibitors in a mouse model of lung adenocarcinoma.
  • 15. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   Inhibition of Cdk1 is likely to sensitise tumours with wild type BRCA1 to PARP inhibition, and that a combination of inhibitors of these two enzymes may be a useful treatment for these tumours
  • 16. OBSERVATION That experiments are fundamental to know how the human life is affected begging in the littlest process that define the whole life
  • 18. MEDICAL UTILITY The study of the human genome could shed any information about each individual and that is where the solution begins each pathology to develop it.
  • 19. MEDICAL UTILITY New experiments with enzymes have led to cures for various types of cancer, starting with the molecular basis of such tumors which involve cell division and proper transfer of genetic information. Molecular biology is the basis for understanding the processes that lead to cause such conditions, so find a solutions or improvements to the health of people
  • 20.